InvestWiser

Vitrolife AB

VITRNasdaq StockholmHealthcareMarket value 15.6 bn SEK
117.70SEK 0.0%
last day · Price as of 18 November 2026

The answer first

Does Vitrolife beat the market?

No, Vitrolife has not beaten the market over the last year.

Vitrolife−14.8%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 37% of Nordic stocks

    • Quality53
    • Value14
    • Trend69

    No. 87 of 195 in healthcare

  • Expectations in the price

    High expectations

    For the share to return about 9% a year from today's price, the cash Vitrolife keeps must grow about 11% a year for 10 years.

Max for seven days

Follow Vitrolife with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Vitrolife

From today, at a price of 117.70 SEK. Write why you follow Vitrolife, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Vitrolife

Your first answer is free, no account needed.

Do you own Vitrolife, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Vitrolife and a few more. Free, no card.

Past year against the exchange and Super Stock
Vitrolife−14.8%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Vitrolife has fallen 14.8% over the past year, including dividends.
  • Overall, Vitrolife ranks better than 37% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 72.5%. The price is 78.6% below its peak now.

What do analysts think of Vitrolife?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

37

Quality, value and trend together. Better than 37% of Nordic stocks.

No. 87 of 195 in healthcare

Quality53
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 125 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.21
  • Asset turnoverSales divided by everything the company owns0.30
  • Return on equityProfit divided by equity−61.1%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value14
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 124 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity1.9
  • P/SPrice divided by sales4.5
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flow22.3

The ranking is built on P/E, P/B and P/S.

Trend69
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 54 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+29.3%
  • 6 months+12.7%
  • 9 months+30.7%
  • 12 months−14.8%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+20.4%
3 years, per year
−8.5%
5 years, per year
−25.3%
10 years, per year
+4.9%
Largest fall, 3 years
−72.5%
From a peak to the bottom
From the peak now
−78.6%
How far the price is from the peak
Volatility, 1 year
41.0%
How much the price swings over a year
Beta, 1 year
0.59
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Vitrolife

27 funds we follow own Vitrolife. The share is how much of the fund the stock makes up.

  • Norway2
  • Sweden24
  • Denmark1
  • 1 ETF

From the funds' latest known holdings.

About Vitrolife

Vitrolife AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1,100 employees.

Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.

See the full analysis of Vitrolife.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market